Navelbine (Vinorelbine Tartrate)

Vinorelbine Tartrate, the active ingredient in Navelbine, is a Vinca alkaloid presented as an oral formulation for use in cancer therapy. It is employed in the treatment of certain solid tumours, notably non‑small cell lung cancer and metastatic breast cancer, in adult patients.

GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support safe import and use through its global distribution network.

Vinorelbine is a Vinca alkaloid antineoplastic agent used in the management of solid tumours.

- Non‑small cell lung cancer: used as first‑line or second‑line therapy to reduce tumor burden and improve progression‑free survival. - Metastatic breast cancer: administered to control disease spread and alleviate symptoms in patients with prior chemotherapy. - Combination chemotherapy for solid tumours: incorporated with agents such as cisplatin or gemcitabine to enhance overall cytotoxic response. - Advanced NSCLC in combination regimens: contributes to response rates when given with other antineoplastic drugs.

Vinorelbine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: reduced neutrophil count leading to increased infection risk. - Nausea: feeling of sickness often accompanied by an urge to vomit. - Vomiting: expulsion of stomach contents, may be acute or delayed. - Constipation: difficulty passing stools, sometimes requiring laxatives.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count, requiring urgent medical attention. - Severe infection: opportunistic infections due to immunosuppression. - Pulmonary toxicity: inflammation or fibrosis of lung tissue that can impair breathing.

When prescribing vinorelbine, several safety considerations should be observed to minimise risk.

- Blood count monitoring: perform complete blood counts regularly to detect neutropenia. - Liver function assessment: evaluate hepatic enzymes before and during therapy. - Pulmonary evaluation: screen for existing lung disease prior to initiation. - Bone marrow suppression: avoid in patients with severe marrow compromise. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Vinorelbine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase vinorelbine plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce drug exposure. - Concurrent myelosuppressive agents (e.g., cyclophosphamide, doxorubicin): heighten risk of severe bone‑marrow toxicity. - Other Vinca alkaloids (e.g., vincristine, vinblastine): additive neurotoxicity. - Monoclonal antibodies affecting bone marrow (e.g., bevacizumab): may exacerbate hematologic effects.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may modestly raise vinorelbine concentrations. - NSAIDs (e.g., ibuprofen): can increase risk of gastrointestinal toxicity.